Cullinan Therapeutics
Michael Baranello possesses extensive experience in the pharmaceutical and biotech industries, currently working in Search and Evaluation at Cullinan Oncology since February 2022. Prior roles include positions in Competitive Intelligence at Boehringer Ingelheim, R&D Planning and Operations at Regeneron Pharmaceuticals, and Scientist at Hemogenyx Pharmaceuticals, focusing on bispecific antibody development. Michael's background encompasses a postdoctoral fellowship and research in tissue-targeting protein discovery at Alexion Pharmaceuticals and the University of Rochester, building a foundation in drug delivery technologies. Educational qualifications include a Ph.D. and M.S. in Chemical Engineering from the University of Rochester, along with a B.S. in Chemical Engineering from the University of Minnesota.
This person is not in the org chart
This person is not in any teams
Cullinan Therapeutics
1 followers
Cullinan Therapeutics is dedicated to creating new standards of care for patients. We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications.